Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia - PubMed (original) (raw)
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Lisa Kujawski et al. Blood. 2008.
Abstract
Chronic lymphocytic leukemia (CLL) has a variable clinical course. Presence of specific genomic aberrations has been shown to impact survival outcomes and can help categorize CLL into clinically distinct subtypes. We studied 178 CLL patients enrolled in a prospective study at the University of Michigan, of whom 139 and 39 were previously untreated and previously treated, respectively. We obtained unbiased, high-density, genome-wide measurements of subchromosomal copy number changes in highly purified DNA from sorted CD19(+) cells and buccal cells using the Affymetrix 50kXbaI SNP array platform (Santa Clara, CA). Genomic complexity scores were derived and correlated with the surrogate clinical end points time to first therapy (TTFT) and time to subsequent therapy (TTST): measures of disease aggressiveness and/or therapy efficaciousness. In univariate analysis, progressively increasing complexity scores in previously untreated CLL patients identified patients with short TTFT at high significance levels. Similarly, TTST was significantly shorter in pretreated patients with high as opposed to low genomic complexity. In multivariate analysis, genomic complexity emerged as an independent risk factor for short TTFT and TTST. Finally, algorithmic subchromosomal complexity determination was developed, facilitating automation and future routine clinical application of CLL whole-genome analysis.
Figures
Figure 1
The 50k SNP array platform can detect single copy chromosomal differences in the CLL genome with high sensitivity and specificity. DNA from FACS-sorted CD19+ cells and buccal cells was extracted and prepared for hybridization to the 50kXbaI SNP chips as per manufacturer's recommendation. Copy number estimates for each SNP position were calculated using dChipSNP and displayed for all SNP positions, for all patients, for the indicated chromosomes. Copy losses are displayed with blue colors; copy gains, with red colors. The physical position of SNPs is not linear along the displayed portions of the chromosome. (A) Chromosome X. Color-coded copy number estimates are grouped by the known sex of the patients. Red asterisks indicate females with LOH at chromosome X indicating loss. The estimated copy numbers for all SNP positions for CLL no. 105 are displayed along the entire chromosome to the right of the X chromosome display, with the red line indicating the 2N state. (B) Chromosome 12. All patients with FISH results positive for trisomy 12 are grouped on the left of the image. The estimated copy numbers for all SNP positions for CLL no. 143 is shown along the entire chromosome to the right of the chromosome 12 display, with the red line indicating the 2N state. Sporadic subchromosomal copy losses are encircled with red ovals. The approximate position of the clinically used trisomy 12 FISH probe is indicated.
Figure 2
The visual complexity score based on losses predicts for a short time to first therapy in univariate analysis in a cohort of previously untreated CLL patients (Kaplan-Meier plots). The numbers of subchromosomal genomic losses for each patient were determined using 50kXbaI SNP array technology as described in “Derivation of a genomic complexity score, Visual methods” and the mean number of losses as determined by 2 independent observers correlated against the clinical end point time to first therapy (TTFT). Depicted are Kaplan-Meier estimates (A-F) for increasing complexity score cutoffs (eg, < N vs ≥ N lesions per genome) and TTFT estimates (months).
Figure 3
The visual complexity score based on losses predicts for a short time to subsequent therapy in univariate analysis in a cohort of previously treated CLL patients (Kaplan-Meier plots). The numbers of subchromosomal losses were determined using 50kXbaI SNP array technology for each patient as described in “Derivation of a genomic complexity score, Visual method,” and the mean number of losses as determined by 2 independent observers correlated against the clinical end point time to subsequent therapy (TTST). Depicted are Kaplan-Meier estimates (A-F) for increasing complexity score cutoffs (eg, < N vs ≥ N lesions per genome) and TTST estimates (months).
Comment in
- Genomic complexity in chronic lymphocytic leukemia.
Kipps TJ. Kipps TJ. Blood. 2008 Sep 1;112(5):1550. doi: 10.1182/blood-2008-06-156729. Blood. 2008. PMID: 18725569 No abstract available.
Similar articles
- ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. Wiestner A, et al. Blood. 2003 Jun 15;101(12):4944-51. doi: 10.1182/blood-2002-10-3306. Epub 2003 Feb 20. Blood. 2003. PMID: 12595313 - CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM, Jurlander J, Geisler CH, Pedersen LB, Andersen MK, Josefsson P, Petersen JH, Leffers H. Buhl AM, et al. Eur J Haematol. 2006 Jun;76(6):455-64. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2530.x. Epub 2006 Mar 9. Eur J Haematol. 2006. PMID: 16529606 - TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia.
Yi S, Yu Z, Zhou K, Wang Y, An G, Li Z, Zou D, Qi J, Zhao Y, Chan WC, Qiu L. Yi S, et al. Leuk Lymphoma. 2011 Jan;52(1):72-8. doi: 10.3109/10428194.2010.531411. Epub 2010 Dec 6. Leuk Lymphoma. 2011. PMID: 21133733 - [Research progress on prognostic markers of chronic lymphocytic leukemia].
Mao J, Mao ZR, Zhou R. Mao J, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 May;39(3):250-6. doi: 10.3785/j.issn.1008-9292.2010.03.007. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010. PMID: 20544986 Review. Chinese. - Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.
Jain N, Lamanna N. Jain N, et al. Curr Oncol Rep. 2009 Sep;11(5):353-9. doi: 10.1007/s11912-009-0048-9. Curr Oncol Rep. 2009. PMID: 19679010 Review.
Cited by
- The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications.
Mirandari A, Parker H, Ashton-Key M, Stevens B, Walewska R, Stamatopoulos K, Bryant D, Oscier DG, Gibson J, Strefford JC. Mirandari A, et al. Explor Target Antitumor Ther. 2024;5(4):877-901. doi: 10.37349/etat.2024.00253. Epub 2024 Jul 23. Explor Target Antitumor Ther. 2024. PMID: 39280243 Free PMC article. Review. - Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Seymour JF, et al. Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014. Blood. 2022. PMID: 35605176 Free PMC article. Clinical Trial. - The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.
Pérez-Carretero C, González-Gascón-Y-Marín I, Rodríguez-Vicente AE, Quijada-Álamo M, Hernández-Rivas JÁ, Hernández-Sánchez M, Hernández-Rivas JM. Pérez-Carretero C, et al. Diagnostics (Basel). 2021 May 10;11(5):853. doi: 10.3390/diagnostics11050853. Diagnostics (Basel). 2021. PMID: 34068813 Free PMC article. Review. - Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.
Ramos-Campoy S, Puiggros A, Beà S, Bougeon S, Larráyoz MJ, Costa D, Parker H, Rigolin GM, Ortega M, Blanco ML, Collado R, Salgado R, Baumann T, Gimeno E, Moreno C, Bosch F, Calvo X, Calasanz MJ, Cuneo A, Strefford JC, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Espinet B. Ramos-Campoy S, et al. Haematologica. 2022 Mar 1;107(3):593-603. doi: 10.3324/haematol.2020.274456. Haematologica. 2022. PMID: 33691382 Free PMC article. - The Genomic Landscape of Centromeres in Cancers.
Saha AK, Mourad M, Kaplan MH, Chefetz I, Malek SN, Buckanovich R, Markovitz DM, Contreras-Galindo R. Saha AK, et al. Sci Rep. 2019 Aug 2;9(1):11259. doi: 10.1038/s41598-019-47757-6. Sci Rep. 2019. PMID: 31375789 Free PMC article.
References
- Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815. - PubMed
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234. - PubMed
- Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206. - PubMed
- Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847. - PubMed
- Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA046592/CA/NCI NIH HHS/United States
- R21 CA124420/CA/NCI NIH HHS/United States
- 5 P30 CA46592/CA/NCI NIH HHS/United States
- R21 CA124420-01A1/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials